ALLSCHWIL, SWITZERLAND - 02 March 2017 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted a label extension for dosage and administration for "Epoprostenol ACT" (0.5 mg and 1.5 mg) for the treatment of pediatric patients with pulmonary arterial hypertension (PAH). Dr. Satoshi Tanaka, President of Actelion Japan and Chairman of Actelion South Korea, commented: "Epoprostenol ACT" is the first epoprostenol to receive the pediatric indication in Japan. Adding this patient population to the product label allows us to offer physicians in Japan an option for intravenous therapy for young patients with advanced pulmonary arterial hypertension....
↧